Trabectedin

• CAT Number: I000554
• CAS Number: 114899-77-3
• Molecular Formula: C39H43N3O11S
• Molecular Weight: 761.84
• Purity: ≥95%
• Target: Apoptosis Inducers
• Solubility: 10 mM in DMSO
• Storage: Store at -20°C
• IC50: 0.1-3.7 nM (breast cancer cell lines)
• SMILES: CC1=C(OC)C(O)=C2C3[C@@H]4[C@@H]5C6=C(C7=C(OCO7)C(C)=C6OC(C)=O)[C@@H](COC(C8(C9=CC(OC)=C(O)C=C9CCN8)CS5)=O)N4C(O)C(CC2=C1)N3C

Trabectedin (cas 114899-77-3) is a novel antitumour agent of marine origin with potent antitumour activity both in vitro and in vivo.


Clinical trial: A Study to Assess the Potential Effects of Rifampin on the Pharmacokinetics of Trabectedin in Patients With Advanced Malignancies. Phase 1/2

Reference

1: Colmegna B, Uboldi S, Frapolli R, Licandro SA, Panini N, Galmarini CM, Badri
N, Spanswick VJ, Bingham JP, Kiakos K, Erba E, Hartley JA, D/’Incalci M. Increased
sensitivity to platinum drugs of cancer cells with acquired resistance to
trabectedin. Br J Cancer. 2015 Dec 22;113(12):1687-93. doi: 10.1038/bjc.2015.407.
Epub 2015 Dec 3. PubMed PMID: 26633559; PubMed Central PMCID: PMC4701998.
2: De Sanctis R, Marrari A, Marchetti S, Mussi C, Balzarini L, Lutman FR, Daolio
P, Bastoni S, Bertuzzi AF, Quagliuolo V, Santoro A. Efficacy of trabectedin in
advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma. Drug Des Devel
Ther. 2015 Oct 27;9:5785-91. doi: 10.2147/DDDT.S92395. eCollection 2015. Erratum
in: Drug Des Devel Ther. 2016;10:441. PubMed PMID: 26604682; PubMed Central
PMCID: PMC4629957.
3: Guo Z, Wang H, Meng F, Li J, Zhang S. Combined Trabectedin and anti-PD1
antibody produces a synergistic antitumor effect in a murine model of ovarian
cancer. J Transl Med. 2015 Jul 29;13:247. doi: 10.1186/s12967-015-0613-y. PubMed
PMID: 26219551; PubMed Central PMCID: PMC4517526.
4: Leporini C, Patanè M, Saullo F, Rende P, Gallelli L, Di Paola ED, Toscano R,
Lucia M, Rossi M, De Sarro G, Russo E. A comprehensive safety evaluation of
trabectedin and drug-drug interactions of trabectedin-based combinations.
BioDrugs. 2014 Dec;28(6):499-511. doi: 10.1007/s40259-014-0100-7. Review. PubMed
PMID: 25209722.
5: D/’Incalci M. Trabectedin mechanism of action: what/’s new? Future Oncol. 2013
Dec;9(12 Suppl):5-10. doi: 10.2217/fon.13.207. Review. PubMed PMID: 24195524.
6: Hoiczyk M, Grabellus F, Podleska L, Ahrens M, Schwindenhammer B, Taeger G,
Pöttgen C, Schuler M, Bauer S. Trabectedin in metastatic soft tissue sarcomas:
Role of pretreatment and age. Int J Oncol. 2013 Jul;43(1):23-8. doi:
10.3892/ijo.2013.1928. Epub 2013 May 2. PubMed PMID: 23652821; PubMed Central
PMCID: PMC3742158.
7: Germano G, Frapolli R, Belgiovine C, Anselmo A, Pesce S, Liguori M, Erba E,
Uboldi S, Zucchetti M, Pasqualini F, Nebuloni M, van Rooijen N, Mortarini R,
Beltrame L, Marchini S, Fuso Nerini I, Sanfilippo R, Casali PG, Pilotti S,
Galmarini CM, Anichini A, Mantovani A, D/’Incalci M, Allavena P. Role of
macrophage targeting in the antitumor activity of trabectedin. Cancer Cell. 2013
Feb 11;23(2):249-62. doi: 10.1016/j.ccr.2013.01.008. PubMed PMID: 23410977.